Log in to your Inderes Free account to see all free content on this page.
AlzeCure Pharma
1.48 SEK
+5.71 %
Less than 1K followers
ALZCUR
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AlzeCure Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -50.6 | -71.1 | -77.4 | -55.9 | -37.8 | -36.1 | -46.6 |
| EBIT | -50.9 | -71.6 | -77.9 | -56.4 | -38.3 | -36.1 | -47.9 |
| Profit before taxes | -50.9 | -71.4 | -77.8 | -56.2 | -37.2 | -35.2 | -47.7 |
| Net income | -50.9 | -71.4 | -77.8 | -56.2 | -37.2 | -35.2 | -47.7 |
| EPS | -1.16 | -1.63 | -1.77 | -1.06 | -0.54 | -0.44 | -0.47 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | -27.9 % | -64.4 % | -235.9 % | -93.0 % | -156.4 % | -134.5 % | -144.8 % |
| ROI | -27.2 % | -60.6 % | -170.4 % | -79.4 % | -116.2 % | -102.3 % | -80.7 % |
Login required
This content is only available for logged in users